Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
887.16
+1.61 (+0.18%)
Official Closing Price
Updated: 4:10 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Today 4:45 EDT
Investors can find market-trouncing blue chip stocks in the healthcare industry.
Via
The Motley Fool
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
October 04, 2024
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over...
Via
Benzinga
Exposures
Product Safety
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
October 04, 2024
Via
Benzinga
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
October 04, 2024
NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss. Digital clinics and multidisciplinary teams will deliver the drug to...
Via
Benzinga
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via
Investor's Business Daily
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
October 03, 2024
Via
Benzinga
Eli Lilly's Options: A Look at What the Big Money is Thinking
October 01, 2024
Via
Benzinga
Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
September 30, 2024
Via
Benzinga
Massive News for Hims & Hers Stock: The Truth About Today's Move
October 04, 2024
Hims & Hers may not be hurt by GLP-1 news the way investors think.
Via
The Motley Fool
Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
October 03, 2024
Texas Attorney General Ken Paxton sues major insulin manufacturers and PBMs, accusing them of conspiring to inflate insulin prices by as much as 1,000%, violating Texas law and harming diabetes...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
October 03, 2024
Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to adverse effects, costs, and unmet expectations, raising concerns about...
Via
Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
October 03, 2024
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli Lilly And Co's (NYSE:LLY) weight-loss and diabetes drugs from its shortage...
Via
Benzinga
This IPO Biotech Stock Could Be the Next Eli Lilly
October 03, 2024
BioAge has its eyes on a handful of truly gargantuan markets.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
October 02, 2024
RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing growth opportunities in the U.S. Type 1 and Type 2 diabetes markets, product...
Via
Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
October 02, 2024
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.
Via
Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
October 02, 2024
Eli Lilly announces a $4.5B investment to build the Lilly Medicine Foundry, a state-of-the-art facility in Indiana. The new center will focus on advanced drug development and manufacturing, reinforcing...
Via
Benzinga
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
October 02, 2024
Eli Lilly is on track to become the first trillion-dollar pharma company, fueled by FDA-approved weight loss drugs. With a current valuation of $842 billion, analysts weigh investor risks as...
Via
Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients
October 01, 2024
Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent health risks. CEO Dave Ricks emphasizes responsible use amid supply concerns.
Via
Benzinga
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
October 01, 2024
Currently, the BMI cut-off for trials is 27 in the U.S. and northern Europe.
Via
Benzinga
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
September 30, 2024
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC...
Via
Benzinga
Exposures
Product Safety
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting...
Via
Benzinga
This Is the Best Pharma Stock to Invest $1,000 in Right Now
September 29, 2024
Eli Lilly could keep growing for years without changing its strategy.
Via
The Motley Fool
Eli Lilly And Co DCF Valuation: Is The Stock Undervalued?
September 29, 2024
Based on the DCF valuation, the stock is overvalued. The DCF value of $632.57 share is lower than the current market price of $921.49. The Margin of Safety is -45.67%.
Via
Talk Markets
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
September 28, 2024
These two players are set on finding the next big therapeutic modality.
Via
The Motley Fool
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
September 28, 2024
It's hard to bet against this company right now.
Via
The Motley Fool
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
September 28, 2024
Eli Lilly and Lululemon operate in very different industries, but both are on promising trajectories.
Via
The Motley Fool
Stocks To Buy And Hold For 5 Years
September 27, 2024
Growth potential is key for investors who want to buy and hold for 5 years.
Via
Talk Markets
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
September 27, 2024
Eli Lilly is focusing on research and manufacturing.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.